WALTHAM, Mass., April 28, 2008 (PRIME NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN) (XSSE:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, will report first quarter 2008 results on Monday, May 5, 2008. A conference call and webcast will begin at 2:00 p.m. EDT (11:00 a.m. PDT), hosted by OXiGENE's President and Chief Executive Officer, Dr. Richard Chin; Chief Scientific Officer, Dr. David Chaplin; Chief Medical Officer, Dr. Patricia Walicke; Chief Business Officer, John Kollins and Chief Financial Officer, James Murphy.
